Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Yourgene Health Plc LSE:YGEN London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.20 -1.1% 18.05 1,013,981 16:35:20
Bid Price Offer Price High Price Low Price Open Price
17.50 18.00 18.25 17.75 18.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.61 -3.38 -0.40 130
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:20 UT 27,000 18.05 GBX

Yourgene Health (YGEN) Latest News (4)

More Yourgene Health News
Yourgene Health Takeover Rumours

Yourgene Health (YGEN) Discussions and Chat

Yourgene Health Forums and Chat

Date Time Title Posts
22/9/202022:49YGEN472
20/5/202007:42YourGene to Infinity2,121
04/5/202008:06Partnership with Novacyt 2
30/3/202008:20Yourgene Health at the UK Investor Show3

Add a New Thread

Yourgene Health (YGEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-09-22 15:35:2018.0527,0004,873.50UT
2020-09-22 15:29:2017.7210,0001,772.00O
2020-09-22 14:49:3217.725,000886.00O
2020-09-22 14:37:2317.7233,8605,999.99O
2020-09-22 14:34:3317.502,608456.40O
View all Yourgene Health trades in real-time

Yourgene Health (YGEN) Top Chat Posts

DateSubject
22/9/2020
09:20
Yourgene Health Daily Update: Yourgene Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker YGEN. The last closing price for Yourgene Health was 18.25p.
Yourgene Health Plc has a 4 week average price of 16.63p and a 12 week average price of 15.70p.
The 1 year high share price is 23.50p while the 1 year low share price is currently 7.25p.
There are currently 719,509,950 shares in issue and the average daily traded volume is 4,737,374 shares. The market capitalisation of Yourgene Health Plc is £129,871,545.98.
22/9/2020
22:49
catch007: timojelly: Same share capital however Nasdaq listing creates a greater demand pool. Healthcare is highly rated in US and YGEN would gain greater exposure and hopefully traction in the share price. GL
07/9/2020
19:15
cautioussid: Just posted on LSE: What drives a share price higher is when there are more buyers than sellers. This is not the case here, and until things change, that will be the situation. This Company is well under the radar of the general investor. Once we get a little publicity, bringing it to the attention of speculators, the herd will awaken and they will be all over us. Having had my patience severely tested as a long time holder of shares in Srsp, waiting twelve months for a £1 share price is easy peasy. Think medium to long. Edit: It would appear that an anonymous member has given me the downward thumb - I wonder why?
18/8/2020
10:56
the abbot: What are your thoughts chaps, email to Lyn? On the 25th March Yourgene’s share price hit a high of 25p today we are at sub 17p or thereabouts. Additionally, since the 25th March we have had the following news releases. 1. RNS contract Manufacturing agreement with NCYT. 2. RNS positive presentation on 'adapting during crisis' 3. RNS year eand trading update - Revenues increase 86% 4. RNS Covid-19 testing service launch and a business update. 5. RNS CE-IVD mark received for illumina-based IONA test 6. RNS Collaboration in COVID-19 testing (caxton) 7. RNS Covid-19 assay launched 8. RNS appointment of Joint Broker 9. RNS CE-IVD Mark for ClarigeneT Sars-Cov-2 test 10. RNS £16.15m placing at zero discount and acquisition 11. RNS TGA approval in Australia for IONA Nx sale All RNS'd. 1. Now I would consider any one RNS’s to be received by the market as good news, put together as a group, I consider the group as just so spectacular as to consider the share price might have gone stratospheric. Why do you think it has not? 2. Why is it that you have refused to promote your company surrounding the Covid-19 developments? As a note, every other company that has ‘marketed̵7;, whilst creating a little more volatility, has enabled every one of them, without exception, to raise capital at a vastly increased price and thus reduce dilution to the shareholder. 3. On the basis that very little buying exists in the market for Yourgene’s shares - Please could you explain when and what information was shared with the institutions to get the placing away, did you ever share the same information with the private investors. If yes, why did the institutions buy when the private investors do not? 4. Do you believe that share price growth is an aim of the company,? if yes and none of the 11 points listed above has done anything to support this, what do you plan to do differently to achieve this aim?
14/8/2020
13:07
phatomtraider: Busted a gut laughing at these share trading experts turning a blind eye to share price being manipulated and shafted by Management. Seems like they've been given a blank cheque by PIs to get away with any level of incompetence on poor communications and low share price growth. PIs here are just praying in the corner "it's okay, it's okay I will still get 50p in a couple years time" when they could've gotten the same share price growth with any other recovery stock or COVID stock this year.
30/6/2020
07:15
ngen yap: Great news. Definitely shows the company delivers against its ambitions. This is yet another product / service in our portfolio. Lots of hints in RNS re its potential and route to market. Not bothered with day-to-day share price movements. Confident of mid to long term prospects, which will ultimately lead to share price appreciation.
27/6/2020
12:37
pedr01: Just randomly searching around and located this article from Mark Street-Docherty (CEO of Elucigene) from 2 years ago. What I found interesting is the statement "The average industry revenue growth for UK companies working in in vitro diagnostics stands at 7 per cent." YGENs average revenue growth for the past 4 years of 52% CAGR (£3.1m to £16.6m in 4 years), together with a clearly defined growth strategy and the bonus covid work, demonstrates just what a jewel we have. The share price might be slightly disappointing currently, but I trust the company to just get on with business and the share price will eventually take care of itself. hTTps://medtechengine.com/article/think-globally-to-buck-brexit-inertia/ All IMHO of course.
24/6/2020
15:15
gnnmartin: I was wondering much the same. Perhaps part of the reason is that lots of people were holding on for the clearance to market our test in the EU, expecting that would boost the share price. Unfortunately most people who follow the stock already held, and so the share price didn't rect upwards, and disappointed shareholders are moving on.
23/6/2020
16:30
phatomtraider: Why don't we agree that the share price has doubled since March '20 alone? This way you can ramp away by selecting conveniently from the share charts and I don't need to spend the 2 hours I did the other day to go through the last 4 years of RNS on the NIPT ticker to compare against the share movements to be able to fact check and understand the narrative better. I think Buffet said that “The stock market is designed to transfer money from the active to the patient.” So with the 1% share price growth that has accompanied each of the recent high-level RNS I am sure we will pull off a Novacyt here one day, eventually.
15/6/2020
08:47
ngen yap: Great news. Markets are down, but when it recovers, YGEN share price will react accordingly. The only blue in my entire watchlist!
19/4/2019
19:11
scotty1: Another good reasoned post from notaflipper over the road. Obviously there's a lot of information to take in so let's go through the deal the circa 20% share expansion and TW's valuation. If I am honest TW's reaction seems very stage managed. Having known the Trading Statement date he was probably aware hence making this his 'nap' tick for end of April. Otherwise him, and other backroom commentators, expectations of a spike would have optimistically been based on the TS alone. Elucigene has launched 36 commercial products. Its main product categories cover Cystic Fibrosis Kits, Rapid Aneuploidy Analysis, Reproductive Health, Genetic Disease Diagnosis. The business was founded 20 years ago by pharmaceutical giant AstraZeneca and has changed hands several times since. In October 2013 the business was established as an independent company, when Scott Higgins, 55, and Mike Webb, 60, led a management buyout backed by Percipient Capital.Gross. Elucigene had a turnover of £3.6m in FY2018 with a with a cost of sales of £500k. This means a Cash Generative business already of surplus £3.1m. Cash is £1.3m, gross and operating profits £0.6 million and net cash is £0.4 million . The company plans to expand internationally and sees South America and India as key markets for its growth. More importantly for YGEN holders it plans to expand into the US this year https://www.elucigene.com/elucigene-targets-us-for-next-stage-of-export-drive/ The Enlarged company though it will have 574,418,577 shares after and potentially a further 11,550,000 if TMO further subscribe will have also the following: Elucigene's product offering plus IONA test plus further product expansions - no long overdue to be announced - such as pre-implantation genetic screening (PGS), Rhesus disease screens, BRAC1 screen and Illumina's version of the IONA test. In total the product portfolio now will be close to 40. The Enlarged company would have sales of £12.5 million in FY2018. Elucigene have no public sales forecasts so even if we assume they're flat at £3.6m the Enlarged Company will have improved sales forecasts of £16.1M in FY2020E and £20.8M in FY2021E. Break-even to be achieved this year. On a fully diluted basis of 586m shares at 17p share price the market capitalisation would be £99.6m. With currently 459m at a proposed share price of 20p the market capitalisation would be £91.8m. TW HAS UPGRADED HIS VALUATION. To be fair to TW the reason his share price targets fail is there's not been much volume. Much of the share price movement has been driven by Steve Myers. With swing traders making up 2/3p movement. Hence the tedious trading pattern between 13.5 to 10.5p since February. On Friday we saw 6m shares traded this bodes well in addition to new investors and a 12 month lock-in period for new shares. Even at 17p this would be very low. With sales of £16m in FY2020E the current share price on a fully diluted basis is £70m. This gives a 4.5 EV/sales multiple of 4.4. At 17p an EV of £99m would be 6. Considering the test volumes will now be in excess of 100k an EV/sales multiple closer to 10x would be fairer. These figures are also conservative because we do not know Elucigene's sales forecasts or the new test volumes expected by new products this year. I suspected that the TW's mood will be come better in the next week or so with a revised broker rating and research note which may be accompanied by further potentially further announcements. Thereafter a stage managed increase in target will predictably ensue.
Yourgene Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
YGEN
Yourgene H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200923 04:29:01